Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.
Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.
The FDA was just told by a federal judge that no, it can't take 75 years to release documents showing the process of Pfizer's COVID-19 vaccine licensing approval that it has to cough up the data within eight months. That's a significant win for open-government advocates.
Hospitalizations of U.S. children under 5 with COVID-19 soared in recent weeks to their highest level since the pandemic began, according to government data released Friday on the only age group not yet eligible for the vaccine.